var data={"title":"Mannitol (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Mannitol (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/771531?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=mannitol-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Mannitol (systemic): Patient drug information&quot;</a> and <a href=\"topic.htm?path=mannitol-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Mannitol (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662085\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Osmitrol;</li>\n      <li>Resectisol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662086\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Osmitrol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662091\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Diuretic, Osmotic;</li>\n      <li>\n        Genitourinary Irrigant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662134\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Intracranial pressure (ICP), cerebral edema, reduction (off-label dosing):</b> IV: 0.25 to 1 g/kg/dose; may repeat every 6 to 8 hours as needed (BTF [Carney 2016]; Grape 2012). Some suggest maintaining serum osmolality &lt;320 mOsm/kg (Rabinstein 2006). However, this value is routinely exceeded without ill effect. A better marker for mannitol toxicity may be the serum osmole gap (or osmolal gap) and the target is &lt;18 to 20 (Erstad 2016; Garc&iacute;a-Morales 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intraocular pressure (IOP), reduction:</b> IV: 1.5 to 2 g/kg administered over 30 to 60 minutes 1 to 1.5 hours prior to surgery</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IOP (traumatic hyphema), reduction:</b> IV: 1.5 g/kg administered over 45 minutes twice daily for IOP &gt;35 mm Hg; may administer every 8 hours in patients with extremely high pressure (Crouch 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Kidney transplant:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Donor: 12.5 g (with adequate hydration) prior to nephrectomy; may repeat (Morris 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Recipient: 50 g before kidney revascularization (Sprung 2000; Tiggeler 1984; van Valenberg 1987; Weimar 1983)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Transurethral irrigation: </b> Use 5% urogenital solution as required for irrigation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662133\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=mannitol-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Mannitol (systemic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intracranial pressure (ICP), reduction:</b> Infants, Children, and Adolescents: IV: Usual range: 0.25 to 1 g/kg/dose infused over 20 to 30 minutes; repeat as needed to maintain serum osmolality &lt;300 to 320 mOsm/kg (BTF [Carney 2016]; Hegenbarth 2008; Kochanek 2012). <b>Note:</b> The manufacturer&rsquo;s labeling allows for higher single doses up to 2 g/kg/dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intraocular pressure (IOP), reduction:</b> Infants, Children, and Adolescents: IV: 1 to 2 g/kg/dose or 30 to 60 g/m<sup>2</sup>/dose infused over 30 to 60 minutes administered 1 to 1.5 hours prior to surgery</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IOP (traumatic hyphema), reduction:</b> Infants, Children, and Adolescents: IV: 1.5 g/kg administered over 45 minutes twice daily for IOP &gt;35 mm Hg; may administer every 8 hours in patients with extremely high pressure (Crouch 1999)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662135\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Consider initiation at lower end of dosing range.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662136\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Contraindicated in severe renal impairment. Use caution in patients with underlying renal disease. May be used to reduce the incidence of acute tubular necrosis when administered prior to revascularization during kidney transplantation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662137\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662152\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Osmitrol: 5% (1000 mL); 10% (500 mL); 15% (500 mL); 20% (250 mL, 500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5% (1000 mL [DSC]); 10% (1000 mL [DSC]); 15% (500 mL [DSC]); 20% (250 mL, 500 mL); 25% (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25% (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Irrigation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Resectisol: 5% (2000 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662089\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662138\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Concentration and rate of administration depends on indication/severity, or may be adjusted to urine flow. For cerebral edema or elevated ICP, administer over 30 to 60 minutes. Inspect for crystals prior to administration. If crystals are present, redissolve by warming solution. Use filter-type administration set (&le;5 micron) for infusion solutions containing mannitol &ge;20% (WHO 2011). Do not administer with blood. Crenation and agglutination of red blood cells may occur if administered with whole blood.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Vesicant (at concentrations &gt;5%); ensure proper catheter or needle position prior to and during IV infusion. Avoid extravasation of IV infusions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote; remove needle/cannula; apply dry cold compresses (Hurst 2004; Reynolds 2014); elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hyaluronidase:</i> Intradermal or SubQ: Inject a total of 1 to 1.7 mL (15 units/mL) as five separate 0.2 to 0.3 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (Reynolds 2014) <b>or</b> SubQ: Administer multiple 0.5 to 1 mL injections of a 15 units/mL solution around the periphery of the extravasation (Kumar 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Irrigation: Administer using only the appropriate transurethral urologic instrumentation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662095\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Reduction of increased intracranial pressure associated with cerebral edema; reduction of increased intraocular pressure; promoting urinary excretion of toxic substances</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Although FDA-labeled indications, the use of mannitol for the prevention of acute renal failure and/or promotion of diuresis is not routinely recommended (Kellum 2008). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary irrigation solution: Irrigation in transurethral prostatic resection or other transurethral surgical procedures</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662096\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Improve renal transplant function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662080\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Osmitrol may be confused with esmolol</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662105\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain, cardiac failure, hypertension, hypotension, local thrombophlebitis, peripheral edema, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, dizziness, headache, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Bullous rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Dehydration (secondary to rapid diuresis), dilutional hyponatremia, electrolyte disturbance (increased osmolar gap), fluid and electrolyte disturbance, hypovolemia (secondary to rapid diuresis), hyperglycemia, hyperkalemia (hyperosmolality-induced), hypernatremia, hypervolemia, metabolic acidosis (dilutional), water intoxication</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dysuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Local pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Acute renal failure, tubular necrosis (adult dose: &gt;200 g/day; serum osmolality &gt;320 mOsm/L), polyuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Pulmonary edema, rhinitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, tissue necrosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662102\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Hypersensitivity to mannitol or any component of the formulation; severe renal disease (anuria); severe dehydration; active intracranial bleeding except during craniotomy; progressive heart failure, pulmonary congestion, or renal dysfunction after mannitol administration; severe pulmonary edema or congestion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary irrigation solution:  Anuria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662103\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Extravasation: Vesicant (at concentrations &gt;5%); ensure proper catheter or needle position prior to and during IV infusion. Avoid extravasation of IV infusions. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fluid/electrolyte loss: Excess amounts can lead to profound diuresis with fluid and electrolyte loss; close medical supervision and dose evaluation are required. Watch for and correct electrolyte disturbances; adjust dose to avoid dehydration. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nephrotoxicity: May cause renal dysfunction especially with high doses; use caution in patients taking other nephrotoxic agents, with sepsis or preexisting renal disease. To minimize adverse renal effects, adjust to keep serum osmolality less than 320 mOsm/L. Discontinue if evidence of acute tubular necrosis. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cerebral edema:  In patients being treated for cerebral edema, mannitol may accumulate in the brain (causing rebound increases in intracranial pressure) if circulating for long periods of time as with continuous infusion; intermittent boluses preferred. Cardiovascular status should also be evaluated; do not administer electrolyte-free mannitol solutions with blood. If hypotension occurs, monitor cerebral perfusion pressure to ensure adequate. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Adequate renal function: Should not be administered until adequacy of renal function and urine flow is established; use 1 to 2 test doses to assess renal response.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662112\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662109\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=109078&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Mannitol (Systemic) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diacerein: May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the adverse/toxic effect of Diuretics. Opioid Analgesics may diminish the therapeutic effect of Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tobramycin (Oral Inhalation): Mannitol (Systemic) may enhance the nephrotoxic effect of Tobramycin (Oral Inhalation). <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662098\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662099\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Reproduction studies have not been conducted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662101\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if mannitol is excreted in breast milk. The manufacturer recommends that caution be exercised when administering mannitol to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662144\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal function, daily fluid I &amp; O, serum electrolytes, serum and urine osmolality. Monitor infusion site.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">For treatment of elevated intracranial pressure, some suggest maintaining serum osmolality &lt;320 mOsm/kg due to the potential risk of acute renal tubular damage (Grape 2012; Rabenstein 2006). However, this value is routinely exceeded without ill effect. A better marker for mannitol toxicity may be the serum osmole gap and the target used by most clinicians is &lt;18 to 20 (Erstad 2016; Garc&iacute;a-Morales 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662120\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Produces an osmotic diuresis by increasing the osmotic pressure of glomerular filtrate, which inhibits tubular reabsorption of water and electrolytes and increases urinary output . Mechanism of action in reduction of intracranial pressure (ICP) is less clear. However, it is thought that mannitol reduces ICP by reducing blood viscosity which transiently increases cerebral blood flow and oxygen transport and constricts pial arterioles. This in turn reduces cerebral blood volume and ICP. Furthermore, mannitol reduces ICP by withdrawing water from the brain parenchyma and excretes water in the urine (Allen 1998; BTF [Carney 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662122\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Diuresis: 1 to 3 hours; Reduction in intracranial pressure: ~15 to 30 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Reduction in intracranial pressure: 1.5 to 6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: 34.3 L; remains confined to extracellular space (except in extreme concentrations); does not penetrate the blood-brain barrier (generally, penetration is low)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Minimally hepatic to glycogen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 0.25 to 1.7 hours; 6 to 36 hours in renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~55% to 87% as unchanged drug) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662154\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Mannitol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20% (250 mL): $23.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25% (50 mL): $2.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Osmitrol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (1000 mL): $54.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (500 mL): $53.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15% (500 mL): $59.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20% (250 mL): $52.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Resectisol Irrigation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (2000 mL): $11.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46972187\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ardeaosmosol MA (CZ);</li>\n      <li>Demanitol (PE);</li>\n      <li>Demanitol AL (PY);</li>\n      <li>Infusan M20 (ID);</li>\n      <li>Isotol (IT);</li>\n      <li>Mannisol (HU);</li>\n      <li>Mannits (EE);</li>\n      <li>Neurotol-M (IN);</li>\n      <li>Osmitrol (AU, IN, KW, NZ, QA, SA, SG);</li>\n      <li>Osmofundin (AT, ES, MY, RO, SG);</li>\n      <li>Osmofundina (PT);</li>\n      <li>Osmokab (MX);</li>\n      <li>Osmorin (PE, PY);</li>\n      <li>Osmosol (BD);</li>\n      <li>Osmosteril (NL);</li>\n      <li>Otsu-manitol (ID);</li>\n      <li>Renitol (PH);</li>\n      <li>Resectisol (TR);</li>\n      <li>Rezosel (TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Allen CH and Ward JD, &ldquo;An Evidence-Based Approach to Management of Increased Intracranial Pressure,&rdquo; <i>Crit Care Clin</i>, 1998, 14(3):485-96.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Badjatia N, Carney N, Crocco TJ, et al, &ldquo;Guideline for Prehospital Management of Traumatic Brain Injury 2nd Edition,&rdquo; <i>Prehosp Emerg Care</i>, 2008, 12(Suppl 1):1-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/18203044/pubmed\" target=\"_blank\" id=\"18203044\">18203044</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brain Trauma Foundation,&quot;Guidelines for the Field Management of Combat-Related Head Trauma,&quot; 2005. Available at http://www.braintrauma.org</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brain Trauma Foundation,&quot;Guidelines for the Management of Severe Traumatic Brain Injury, 4th ed,&quot; 2016. Available at https://braintrauma.org/uploads/03/12/Guidelines_for_Management_of_Severe_TBI_4th_Edition.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratton SL, Chestnut RM, Ghajar J, et al, &ldquo;Guidelines for the Management of Severe Traumatic Brain Injury. II. Hyperosmolar Therapy,&rdquo; <i>J Neurotrauma</i>, 2007, 24(Suppl 1):14-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/17511539/pubmed\" target=\"_blank\" id=\"17511539\">17511539</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crouch ER Jr and Crouch ER, &quot;Management of Traumatic Hyphema: Therapeutic Options,&quot; <i>J Pediatr Ophthalmol Strabismus</i>, 1999, 36(5):238-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/10505828/pubmed\" target=\"_blank\" id=\"10505828\">10505828</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erstad B. Critical care pharmacotherapy. Lenexa, KS: American College of Clinical Pharmacy; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo; <i>Pediatrics</i>, 2008, 121(2):433-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kellum JA, Cerda J, Kaplan LJ, et al, &ldquo;Fluids for Prevention and Management of Acute Kidney Injury,&rdquo; <i>Int J Art Organ</i>, 2008, 31(2):96-110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/18311727/pubmed\" target=\"_blank\" id=\"18311727\">18311727</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <i>Kidney Transplantation: Principles and Practice</i>, 6th ed, Morris PJ and Knechtle SJ, eds, Philadelphia, PA: Saunders, 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kochanek PM, Carney N, Adelson PD, et al, &ldquo;Guidelines for the Acute Medical Management of Severe Traumatic Brain Injury in Infants, Children, and Adolescents -- Second Edition,&rdquo; <i>Pediatr Crit Care Med</i>, 2012, 13(Suppl 1):1-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/22217782/pubmed\" target=\"_blank\" id=\"22217782\">22217782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kumar MM, Sprung J. The use of hyaluronidase to treat mannitol extravasation. <i>Anesth Analg</i>. 2003;97(4):1199-1200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/14500188/pubmed\" target=\"_blank\" id=\"14500188\">14500188</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD, Fleisher LA, Wiener-Kronish JP, et al, eds, Miller&rsquo;s Anesthesia, 7th ed, Philadelphia: Churchill Livingstone, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmitrol (mannitol injection, solution) [prescribing information]. Deerfield, IL: Baxter; May 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palmquist KL, Quattrocchi FP, and Looney LA, &ldquo;Compatibility of Furosemide With 20% Mannitol,&rdquo; <i>Am J Health Syst Pharm</i>, 1995, 52(6):648,50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/7606581/pubmed\" target=\"_blank\" id=\"7606581\">7606581</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Procaccio F, Stocchetti N, Citerio G, et al, &ldquo;Guidelines for the Treatment of Adults With Severe Head Trauma (Part II). Criteria for Medical Treatment,&rdquo; <i>J Neurosurg Sci</i>, 2000, 44(1):11-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/10961491/pubmed\" target=\"_blank\" id=\"10961491\">10961491</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rabinstein AA, &quot;Treatment of Cerebral Edema,&quot; <i>Neurologist</i>, 2006, 12(2):59-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/16534443/pubmed\" target=\"_blank\" id=\"16534443\">16534443</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi: 10.1002/phar.1396.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sprung J, Kapural L, Bourke DL, et al, &quot;Anesthesia for Kidney Transplant Surgery,&quot; <i>Anesthesiol Clin North America</i>, 2000, 18(4):919-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/11094698/pubmed\" target=\"_blank\" id=\"11094698\">11094698</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tiggeler RG, Berden JH, Hoitsma AJ, et al, &quot;Prevention of Acute Tubular Necrosis in Cadaveric Kidney Transplantation by the Combined Use of Mannitol and Moderate Hydration,&quot; <i>Ann Surg</i>, 1985, 201(2):246-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/3918517/pubmed\" target=\"_blank\" id=\"3918517\">3918517</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van Valenberg PL, Hoitsma AJ, Tiggeler RG, et al, &quot;Mannitol as an Indispensable Constituent of an Intraoperative Hydration Protocol for the Prevention of Acute Renal Failure After Renal Cadaveric Transplantation,&quot; <i>Transplantation</i>, 1987, 44(6):784-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/3122381/pubmed\" target=\"_blank\" id=\"3122381\">3122381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weimar W, Geerlings W, Bijnen AB, et al, &quot;A Controlled Study on the Effect of Mannitol on Immediate Renal Function After Cadaver Donor Kidney Transplantation,&quot; <i>Transplantation</i>, 1983, 35(1):99-101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-drug-information/abstract-text/6401883/pubmed\" target=\"_blank\" id=\"6401883\">6401883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO), &quot;18th Expert Committee on the Selection and Use of Essential Medicines: review of the role of mannitol in the therapy of children,&quot; 2011. Available at http://www.who.int/selection_medicines/committees/expert/18/applications/16_Mannitol_review_EMLc.pdf</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 109078 Version 29.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F28662085\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F28662086\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F28662091\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F28662134\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F28662133\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F28662135\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F28662136\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F28662137\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F28662152\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F28662089\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F28662138\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F28662095\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F28662096\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F28662080\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F28662105\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F28662102\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F28662103\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F28662112\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F28662109\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F28662098\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F28662099\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F28662101\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F28662144\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F28662120\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F28662122\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F28662154\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F46972187\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/109078|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=mannitol-systemic-patient-drug-information\" class=\"drug drug_patient\">Mannitol (systemic): Patient drug information</a></li><li><a href=\"topic.htm?path=mannitol-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Mannitol (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}